

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ross Grant Thomas Walker
Date of last notice	9 September 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ross G T Walker Pty Ltd
Date of change	24 November 2021
No. of securities held prior to change	Ross G T Walker Pty Ltd: 4,370,370 Fully paid ordinary shares 450,000 Performance Rights expiring 1 April 2025 1,050,000 Performance Rights expiring 1 April 2025 600,000 Performance Rights expiring 30 June 2024
Class	1. Fully paid ordinary shares 2. Performance Rights expiring 30 June 2024
Number acquired	1. 600,000 Fully paid ordinary shares
Number disposed	2. 600,000 Performance Rights expiring 30 June 2024
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1. Nil – Shares issued on exercise of Performance Rights 2. Nil – Exercise of Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	Ross G T Walker Pty Ltd: 4,970,370 Fully paid ordinary shares 450,000 Performance Rights expiring 1 April 2025 1,050,000 Performance Rights expiring 1 April 2025
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Performance Rights

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.